Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 15 Dec 2022
Dupixent (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
15 December 2022 - Approval based on direct to Phase 3 program showing more than three times as many Dupixent patients ...
Posted by Michael Wonder on 15 Dec 2022
Children, parents protest PHARMAC funding review at Parliament
14 December 2022 - A petition calling on PHARMAC to "fund lifesaving medicines for all New Zealand children" has been ...
Posted by Michael Wonder on 14 Dec 2022
HIRA sets up system to manage 'super-expensive' drugs
14 December 2022 - The Health Insurance Review and Assessment Service (HIRA) said it would operate a system to manage ...
Posted by Michael Wonder on 14 Dec 2022
Agilent Resolution ctDx First receives FDA approval as a liquid biopsy companion diagnostic test for advanced non-small-cell lung cancer
12 December 2022 - Agilent Technologies announced today that the US FDA has approved Agilent Resolution ctDx First as a ...
Posted by Michael Wonder on 14 Dec 2022
More than 5,200 people could benefit after NICE broadens recommendation on chronic lung disease treatment
14 December 2022 - NICE broadens recommendation on chronic lung disease treatment. ...
Posted by Michael Wonder on 14 Dec 2022
PHARMAC to fund the EpiPen for severe allergies
15 December 2022 - PHARMAC has confirmed today that it will be fully funding the EpiPen brand of adrenaline auto ...
Posted by Michael Wonder on 13 Dec 2022
Target trial emulation: a framework for causal inference from observational data
12 December 2022 - Quantifying the effect of a treatment on a clinical outcome—causal inference—requires the comparison of outcomes under different ...
Posted by Michael Wonder on 13 Dec 2022
Galera submits new drug application for avasopasem for severe oral mucositis
12 December 2022 - NDA based on two positive randomised, double-blinded, placebo-controlled trials which enrolled a total of 678 patients. ...
Posted by Michael Wonder on 13 Dec 2022
Enhertu supplemental new drug application submitted in Japan for patients with HER2 mutant metastatic non-small-cell lung cancer
13 December 2022 - Submission based on DESTINY-Lung02 and DESTINY-Lung01 results where Enhertu demonstrated clinically meaningful tumour responses. ...
Posted by Michael Wonder on 13 Dec 2022
EMA publishes agenda for the 12-15 December CHMP meeting
12 December 2022 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 13 Dec 2022
PharmaJet Partner Immunomic Therapeutics receives FDA fast track designation for pDNA vaccine for skin cancer
13 December 2022 - Vaccine exclusively delivered with the PharmaJet Stratis needle-free injection system. ...
Posted by Michael Wonder on 13 Dec 2022
PHARMAC petition: fear tamariki with cancer won’t have access to lifesaving medicines
13 December 2022 - A petition, that will be delivered tomorrow to Parliament, on behalf of Tamariki with cancer, chronic ...
Posted by Michael Wonder on 13 Dec 2022
FDA grants accelerated approval to adagrasib for KRAS G12C mutated NSCLC
12 December 2022 - Today, the FDA granted accelerated approval to adagrasib (Krazati, Mirati Therapeutics), a RAS GTPase family inhibitor, ...
Posted by Michael Wonder on 11 Dec 2022
Lives will continue to be lost to meningococcal disease as PHARMAC funding for vaccines does not go far enough
8 December 2022 - Meningitis Foundation says PHARMAC must make both the meningococcal B and ACWY vaccines available to all ...
Posted by Michael Wonder on 11 Dec 2022
National DNA screening could save lives for people with high risk hereditary disease gene variants
7 December 2022 - The DNA Screen study offers free DNA screening for high risk hereditary disease gene variants to 10,000 ...